The Science of Signals, The Promise of Cures
Advancing precision medicine with multiomics
and AI-powered bioinformatics expertise
The latest from Signios
May 19, 2025
|
Grant Program
Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry’s Largest NGS-Based Proteomics Panel
April 10, 2025
|
Press Release
Signios Bio Launches with AI-Driven Bioinformatics Platform and Multiomics Expertise to Advance Precision Medicine
April 10, 2025
|
NEWS
Global Health Council recognizes Signios Bio as a Health Hero in docuseries by same name
Diverse, multimodal omics data is the path to make the next breakthroughs in drug discovery & precision medicine
+70%
Multiomics integration increases biomarker discovery success rates by 70%
2.6x
Drug targets with genetic support are 2.6 times more likely to succeed in clinical trials
-25%
Effective use of genomics and bioinformatics in drug development can reduce R&D costs by up to 25%
Leveraging cutting-edge multiomics technologies, advanced bioinformatics, and AI-driven insights, we transform complex biological data into actionable breakthroughs that accelerate drug development, diagnostics, and precision medicine
At Signios, we support genetic research for
Sequencing and multiomics solutions to drive discovery in genetic disease research.
Premade Library Sequencing
RNA Sequencing
Whole Exome Sequencing
Sequencing, multiomics, antibody engineering, and real-world evidence to improve discovery & development.
Leverage real-world evidence (RWE) from global research networks across the US, Europe, Asia, Africa, Middle East, and Latin America.
Infrastructure and expertise for partners to develop, validate, and distribute Dx and CDx.
Complement your operations with Lab-in-the-cloud (LINC) modular dry-lab services
Enhanced capabilities with advanced multiomics insights, robust data resources, and streamlined workflows.
Advancing Science in Critical Therapeutic Areas
Oncology
Sequencing capabilities allow for in-depth investigation into tumor genomics, tumor microenvironments, and molecular pathways driving cancer progression
Immunology
Rare Diseases
Whole genome and exome sequencing to enable discovery of novel genetic mutations and understanding the genetic basis of rare disorders
Neurology Disorders
RWE supports epidemiological studies, population health research, and the development of inclusive therapies that address global health disparities
Pharmagenomics & Precision Medicine
Our Customers
Many of the world’s leading academic and biopharmaceutical companies partner with Signios Bio to unlock deeper insights into the biology of disease and enable the future of precision medicine.
Here are just a few.
Our
Science
Our Capabilities
Signios Bio is a leading sequencing service provider based in Foster City, California, offering a wide range of gene and genome sequencing capabilities. Services include whole genome sequencing (WGS), whole exome sequencing (WES), immune repertoire sequencing, epigenomics, and long-read sequencing.
The Foster City laboratory is equipped with high-throughput platforms such as the Illumina NovaSeq X Plus, MiSeq, PacBio Revio, 10X Genomics Chromium, Visium Spatial, and the Sony MA900 Cell Sorter—supporting complex research applications across multiple domains.
Signios Bio also specializes in RNA-Seq, single-cell and spatial transcriptomics, and provides comprehensive bioinformatics analysis with every project. From data processing to customized reporting, the in-house team ensures accurate, actionable results.
Whether you’re looking for DNA sequencing services in the Bay Area or anywhere in the U.S., Signios Bio delivers the technology, expertise, and turnaround times needed to support complex research.
Signios By the Numbers
200+
peer-reviewed publications
1,000+
citations of our work
DNA sequencing assays run
single-cells sequenced
17M+
Unique variants identified
250,000+
transcriptomes sequenced